Enhanced Secretory Leukocyte Protease Inhibitor in Human Immunodeficiency Virus Type 1-Infected Patients
Secretory leukocyte protease inhibitor (SLPI) has been found to possess activity against the human immunodeficiency virus type 1 (HIV-1) in vitro at physiological concentrations. A study was undertaken to evaluate SLPI levels in human saliva and plasma among HIV-positive (HIV(+)) patients with vario...
محفوظ في:
| الحاوية / القاعدة: | Clin Diagn Lab Immunol |
|---|---|
| المؤلفون الرئيسيون: | , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
American Society for Microbiology (ASM)
1999
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC95780/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10548568/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/cdli.6.6.808-811.1999 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|